HT Vista, the pioneer in non-invasive cancer screening for dogs, is set to unveil a groundbreaking enhancement to its device. This latest version not only allows veterinarians to 'rule out' cancer without the need for invasive procedures but now also 'rules in' malignancy with over 90% specificity. This advancement is poised to transform veterinary diagnostics, offering a more streamlined, cost-effective, and precise approach to cancer detection.
HT-Vista’s Cancer Risk Results scale and Mast Cell Tumor identification capability
Key Highlights:
● Unique Offering: HT Vista remains the only tool in the veterinary industry providing non-invasive cancer screening for dermal and subcutaneous masses.
● Enhanced Precision: The new diagnostic capability reduces reliance on costly and invasive techniques like aspiration or biopsy.
● Emotional Impact: This tool alleviates stress for both veterinarians and pet owners, aligning with the needs of clients and providing peace of mind.
Upcoming Launch: The official launch will take place at the Western Veterinary Conference (WVC) on March 2, 2025, where HT Vista will demonstrate this transformational capability. A follow-up webinar with Clinician’s Brief is scheduled for March 20, 2025, to delve deeper into its features and benefits.
Dr Liron Levy-Hirsch MD DVM MRCVS: "We are incredibly excited to enhance our already powerful HT Vista screening tool with a new diagnostic capability, providing veterinary teams with an even more comprehensive decision-support system. Our screening technology has already been a game-changer in early detection, and now, with the ability to flag specific tumor types, we are taking another significant step forward. This advancement empowers veterinary professionals to make even more informed decisions, supports shared decision-making with pet owners, and ultimately improves patient outcomes. By reducing the time from suspicion to diagnosis and treatment, we can detect cancer earlier, avoid the ‘wait and see’ approach, and help save more lives."
Mrs Shani Toledano, CEO and Co-Founder: “The latest HT Vista upgrade transforms cancer detection in veterinary medicine. With enhanced diagnostic capabilities and 90%+ specificity, we empower vets to detect malignancies earlier—without invasive procedures. This breakthrough sets a new standard in veterinary diagnostics, saving more lives with greater confidence.”
As the veterinary industry continues to evolve, innovations like HT Vista's are crucial in improving patient outcomes and enhancing the quality of care. This tool represents a significant step forward in non-invasive diagnostics and a new category of care for the practitioner.
Learn more at ht-vet.com.